Biotech experiments undermine anthropocentrism
Yang Xue 1,2, Hanzhi Yu 3,* and Geng Qin 3, 12-20-2021, 1 Law School, Tianjin University, Tianjin 300072, China; 2 Center for Biosafety Research and Strategy, Tianjin University, Tianjin 300072, China 3 School of Public Affairs, Zhejiang University, Hangzhou 310058, China; https://www.mdpi.com/2071-1050/13/24/14056/htm, "Towards Good Governance on Dual-Use Biotechnology for Global Sustainable Development," Sustainability Volume 13 Issue 24 10.3390/su132414056 (ermo/sms, Acc:6-22-2022)
Although the public now has a clearer understanding of the risks posed by dual-use biotechnology, and the international community has made great efforts to mitigate those risks, disputes over safety and ethics are still common in formulating governance policies worldwide. In the field of stem cell research, the Japanese government revised its “Treatment Policy for Specific Embryos” in 2019, which approved research on cultivating human organs for transplantation in animals by implanting human stem cells into animal embryos. At the same time, it lifted restrictions on the termination of humananimal chimeric embryos within 14 days and restrictions on implanting those embryos into surrogate uteruses [29]. Such embryos may develop into human-animal chimeras, raising ethical disputes over the blurring of boundaries between human and non-human animals. The cause of the governance disputes is that dual-use biotechnology entails human-made risks that are difficult to control in addition to information asymmetry risks. As a result, the traditional self-governance of the biotechnology industry is placed in a predicament where it is difficult for governance models to keep up with the development of emerging technologies.